Processa Pharmaceuticals (NASDAQ: PCSA), the developer of the next-generation chemotherapy drugs that will provide a better safety-efficacy profile than widely used FDA-approved counterparts, will be presenting at the 33rd annual Oppenheimer Healthcare Conference, held on March 14, 2023. According to the announcement, Processa Pharmaceuticals CEO and president Dr. David Young is scheduled for a virtual presentation, which will begin at 12 p.m. EST. The presentation will include an overview of the company’s progress on key programs and upcoming data milestones. A replay of Young’s presentation will be available on the company’s website following its conclusion. In addition, company officials will be available for one-on-one meetings.
To view the presentation, visit https://ibn.fm/z8FX3
To view the full press release, visit https://ibn.fm/7mSXK
About Processa Pharmaceuticals Inc.
Processa Pharmaceuticals has a mission to develop the next-generation chemotherapy drugs that will provide a better safety-efficacy profile than FDA-approved counterparts. These FDA-approved drugs are some of the most widely used chemotherapy drugs for treating various types of cancers. Processa Pharmaceuticals uses its regulatory science approach to develop these drugs in order to achieve high-value milestones effectively and efficiently. Processa’s three next-generation chemotherapy oncology treatment programs are: Next Generation Capecitabine (PCS6422 and Capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers), Next Generation Gemcitabine (PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers) and Next Generation Irinotecan (PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers). For more information, visit the company’s website at www.ProcessaPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork